CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare ConferenceGlobeNewsWire • 06/13/23
This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?The Motley Fool • 06/13/23
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six MonthsInvestors Business Daily • 06/09/23
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) CongressBusiness Wire • 06/09/23
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaBusiness Wire • 06/08/23
Why Is CRISPR Therapeutics AG (CRSP) Up 1.8% Since Last Earnings Report?Zacks Investment Research • 06/07/23
Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying ItThe Motley Fool • 05/21/23